Vgenomics

Vgenomics India Private Limited, a biotechnology firm headquartered in Noida, India, is focused on developing diagnostic and therapeutic solutions for rare inborn diseases. The company was founded in 2021, and incorporated on April 21, 2022, by Dr. Rahila Sardar, Dr. Preeti Gupta Lal, and Sameer Malik. The founding team brings together extensive experience from institutions like Roche, Stanford University, and the Indian Council of Medical Research (ICMR). Dr. Sardar, the CEO, was motivated to start the company after recognizing a lack of dedicated solutions for rare diseases, particularly those affecting children in India. Dr. Lal, the Chief Scientific Officer, is a translational biologist with expertise in data science and clinical biomarker development. Sameer Malik, the Chief Business Officer and an alumnus of the Delhi School of Economics, contributes his background in business strategy, finance, and operations.

The company operates in the personalized medicine market, utilizing next-generation sequencing (NGS) technologies, genomics, and artificial intelligence to shorten the traditionally long diagnosis and treatment timelines for rare genetic conditions. Vgenomics is developing a comprehensive blood test capable of diagnosing over 100 diseases for newborn and parental screening. Their services include Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), and RNA Sequencing, paired with detailed data analysis. The business model is primarily business-to-consumer (B2C), generating revenue from researchers and clinicians at prominent institutions such as AIIMS and PGIMER. Vgenomics also collaborates with industry partners, such as the strategic alliance with Meril Genomics to enhance access to advanced genomic testing like Non-Invasive Prenatal Testing (NIPT) and diagnostics for tuberculosis and other rare diseases across India.

In January 2024, Vgenomics secured an undisclosed amount in a seed funding round led by Mumbai Angels and O2 Angels Network, with participation from other angel investors. This capital is intended to further develop their diagnostic solutions and scale operations. The company’s approach aims to significantly reduce the time for diagnosis and therapeutic development for the millions affected by rare diseases, which are often genetic and present at birth. By providing tools for early detection and personalized treatment, Vgenomics seeks to improve outcomes for patients, particularly children, facing these challenging conditions.

Keywords: rare disease diagnostics, genomic sequencing, personalized medicine, bioinformatics, artificial intelligence, therapeutic solutions, next-generation sequencing, inborn genetic diseases, whole-exome sequencing, RNAseq, clinical genetics, neonatal care, prenatal testing, drug discovery, biotech India, precision medicine, genetic testing, translational genomics, molecular biology, clinical biomarkers